Ramont L - Search Results

1

Matrikines from basement membrane collagens: a new anti-cancer strategy.

Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX. Monboisse JC, et al. Among authors: ramont l. Biochim Biophys Acta. 2014 Aug;1840(8):2589-98. doi: 10.1016/j.bbagen.2013.12.029. Epub 2014 Jan 6. Biochim Biophys Acta. 2014. PMID: 24406397 Review.

2

Implication of interleukin-4 in wound healing.

Salmon-Ehr V, Ramont L, Godeau G, Birembaut P, Guenounou M, Bernard P, Maquart FX. Salmon-Ehr V, et al. Among authors: ramont l. Lab Invest. 2000 Aug;80(8):1337-43. doi: 10.1038/labinvest.3780141. Lab Invest. 2000. PMID: 10950124 Free article.

3

[Serum protein immunofixation in malignant hemopathies other than multiple myeloma and Waldenstrom's macroglobulinemia].

Ramont L, Ngoc PT, Pignon B, Maquart FX. Ramont L, et al. Ann Biol Clin (Paris). 2002 Sep-Oct;60(5):565-70. Ann Biol Clin (Paris). 2002. PMID: 12368142 Free article. French.

4

The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.

Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, Maquart FX, Alix AJ, Monboisse JC. Floquet N, et al. Among authors: ramont l. J Biol Chem. 2004 Jan 16;279(3):2091-100. doi: 10.1074/jbc.M307736200. Epub 2003 Oct 28. J Biol Chem. 2004. PMID: 14583633 Free article.

5

Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.

Ramont L, Pasco S, Hornebeck W, Maquart FX, Monboisse JC. Ramont L, et al. Exp Cell Res. 2003 Nov 15;291(1):1-10. doi: 10.1016/s0014-4827(03)00336-7. Exp Cell Res. 2003. PMID: 14597403

6

Control of melanoma progression by various matrikines from basement membrane macromolecules.

Pasco S, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Among authors: ramont l. Crit Rev Oncol Hematol. 2004 Mar;49(3):221-33. doi: 10.1016/j.critrevonc.2003.09.006. Crit Rev Oncol Hematol. 2004. PMID: 15036262 Review.

7

Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin.

Thevenard J, Floquet N, Ramont L, Prost E, Nuzillard JM, Dauchez M, Yezid H, Alix AJ, Maquart FX, Monboisse JC, Brassart-Pasco S. Thevenard J, et al. Among authors: ramont l. Chem Biol. 2006 Dec;13(12):1307-15. doi: 10.1016/j.chembiol.2006.10.007. Chem Biol. 2006. PMID: 17185226

8

The NC1 domain of type XIX collagen inhibits in vivo melanoma growth.

Ramont L, Brassart-Pasco S, Thevenard J, Deshorgue A, Venteo L, Laronze JY, Pluot M, Monboisse JC, Maquart FX. Ramont L, et al. Mol Cancer Ther. 2007 Feb;6(2):506-14. doi: 10.1158/1535-7163.MCT-06-0207. Mol Cancer Ther. 2007. PMID: 17308049 Free article.

9

The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration.

Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, Floquet N, Schneider L, Ouchani F, Terryn C, Maquart FX, Monboisse JC, Brassart-Pasco S. Thevenard J, et al. Among authors: ramont l. Int J Cancer. 2010 Mar 1;126(5):1055-66. doi: 10.1002/ijc.24688. Int J Cancer. 2010. PMID: 19551865 Free article.

10

The NC1 domain of type XIX collagen inhibits melanoma cell migration.

Toubal A, Ramont L, Terryn C, Brassart-Pasco S, Patigny D, Sapi J, Monboisse JC, Maquart FX. Toubal A, et al. Among authors: ramont l. Eur J Dermatol. 2010 Nov-Dec;20(6):712-8. doi: 10.1684/ejd.2010.1070. Epub 2010 Sep 14. Eur J Dermatol. 2010. PMID: 20840910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page